Search

everythinglearnresearchcommunity

for

Search:↓

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib may help treat severe hair loss, but more research is needed.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Baricitinib may effectively treat oral lichen planus.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.